ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer

sac-TMT, developed by Merck in partnership with Kelun-Biotech, reduced the risk of death by 32% in patients with advanced or recurrent endometrial cancer in the Phase 3 TroFuse-005 trial, meeting the primary endpoints of overall survival and progression-free survival. The trial enrolled about 776 patients previously treated with platinum chemotherapy and anti-PD-1/L1 therapy. Overall survival was 19 months with sac-TMT versus 12.1 months with chemotherapy, and PFS was 7.2 months versus 3.9 months, a 41% reduction in the risk of progression or death. ORR was 35.1% versus 17.3%.